A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL



Eyre, Toby A, Hildyard, Catherine, Hamblin, Angela, Ali, Ayesha S, Houlton, Aimee, Hopkins, Louise, Royston, Daniel, Linton, Kim M, Pettitt, Andrew, Rule, Simon
et al (show 11 more authors) (2019) A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. HEMATOLOGICAL ONCOLOGY, 37 (4). 352 - 359.

[img] Text
TORCH Original Article Hem Onc 2019 R1.docx - Accepted Version

Download (74kB)
Item Type: Article
Uncontrolled Keywords: AZD2014, DLBCL, mTORC1, mTORC2, Vistusertib
Depositing User: Symplectic Admin
Date Deposited: 27 Nov 2019 16:20
Last Modified: 08 Oct 2021 17:12
DOI: 10.1002/hon.2662
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3062566